Slide 1: FY25 Result Presentation
FY25 Result Presentation 27 August 2025 Mach7 Technologies | ASX: M7T
Slide 2: Mach7 Technologies delivers advanced data management and diagnostic viewing solutions
Mach7 Technologies delivers advanced data management and diagnostic viewing solutions to healthcare organisations worldwide.
Slide 3: Agenda
Agenda 1 Business Overview Teri Thomas | CEO 2 FY25 Results Dyan O’Herne | CFO 3 Outlook Unless otherwise stated, all dollar values are in Australian dollars (AUD) 3
Slide 4: Business Overview
Business Overview
Slide 5: Positioning Mach7 for sustainable long-term profitable growth
Positioning Mach7 for sustainable long- term profitable growth New customer- Customer base Leverage global Leadership centric model provides footprint to renewal brings with creation of foundation for optimise fresh skills & customer co-innovation resource perspectives1 designated and product alloca
Slide 6: Strategic Priorities
Strategic Priorities Review market positioning and shift to customer value-centric growth strategy Define & target ideal Transform customer Deliver customer customer profiles (ICP) facing operations compelling innovations Ensure product roadmap, New Flight Crew structure with each New Chief Innovati
Slide 7: Transforming our customer engagement
Transforming our customer engagement Flight Crew - revitalising how Mach7 serves its customers and partners One multi-disciplinary customer designated team Led by Advocate for Customer Experience (ACE) Clear accountability improves support response time Single point of accountability reduces time an
Slide 8: The Mach7 Loop
The Mach7 Loop Our cycle of compounding growth 8
Slide 9: FY25 Results
FY25 Results
Slide 10: FY25 in Review
FY25 in Review Strong foundation in place for driving future growth 1 Delivered solid growth in revenue, CARR and ARR. 2 Demonstrated cost discipline across the year and met guidance for OPEX growth to be less than FY25 revenue growth. 32% 3 Delivered significant profit improvement which drove opera
Slide 11: FY25 Financial Highlights
FY25 Financial Highlights A$33.8M A$25.3M A$30.2M A$23.5M Revenue Recurring Revenue3 CARR4 ARR5 Run Rate +A$4.7M or +16% on PCP1 +A$4.3M or +20% on PCP +A$2.3M or +8% on PCP +A$1.5M or +7% on PCP In line with FY25 75% of total revenue In line with updated Guidance2 FY25 Guidance2 (FY24: 72%) 80% of
Slide 12: 16% Revenue Growth on PCP
16% Revenue Growth on PCP Recurring revenue up 20% on PCP High quality recurring revenue covers 80% OPEX 35 90% • Revenue of A$33.8M, up 16% on PCP (FY24: 80% 80% A$29.1M). In line with FY25 guidance. 30 72% 70% 63% Recurring Revenue of A$25.3M, up 20% on PCP, OPEX % recurring revenue • 61% 63% acco
Slide 13: Foundational book of business
Foundational book of business Strong growth in expansions and add-ons highlights increased usage by existing customers • Sales orders of A$29.1M (TCV1) compared to A$61.3M in FY24 which was a record year for Mach7 with a large renewal program representing 61% of sales orders (A$38M). 49% 58% 32% • A
Slide 14: Strong revenue growth and cost discipline drive EBITDA improvement
Strong revenue growth and cost discipline drive EBITDA improvement Achieved objective of being operating cash flow positive in FY25 Earnings (A$M)1 FY25 FY24 $ Change % Change • OPEX growth of 9% in line with FY25 guidance for OPEX growth to be less than revenue growth. Cost discipline Revenue 33.8M
Slide 15: Outlook
~ : : \ Aimact7 a >| glist 7 "3 43 ‘ aN Outlook
Slide 16: Outlook
Outlook • As demand for imaging continues to grow in both diagnostic frequency and clinical importance, Mach7 is well placed as a partner of choice for providers worldwide. • New customer engagement model designed to drive improvements in customer satisfaction and the Mach7 Loop. • Mach7 will levera
Slide 17: Contact Us
Contact Us Investor Relations, Mach7 Françoise Dixon +61 (0) 412 292 977 ir@mach7t.com Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000 This document was authorised for release to the ASX by Teri Thomas, Managing Director and Chief Executive Officer Mach7 Technologies
Slide 18: Disclaimer
Disclaimer “Forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date